Elutia Inc. (ELUT): Cash & Equivalents
$36.35M
As of 2025-12-31
$19.90M
As of 2026-06-30
+28.9%
3-year compound annual growth
-1.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $36.35M | +174.6% | 2026-03-13, Balance as of period end |
| 2024-12-31 | $13.24M | -31.3% | 2026-03-13, Balance as of period end |
| 2023-12-31 | $19.28M | +13.5% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $16.99M | -44.1% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $30.39M | -22.4% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $39.15M | n/m | 2022-03-08, Balance as of period end |
| 2019-12-31 | $2.48M | n/a | 2021-03-15, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Elutia Inc. (ELUT) | 2025-12-31 | $36.35M | +174.6% |
| Passage BIO, Inc. (PASG) | 2025-12-31 | $46.30M | +23.2% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $17.47M | -66.1% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $20.95M | -50.0% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $36.79M | +38.1% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $16.42M | -66.0% |
| Armata Pharmaceuticals, Inc. (ARMP) | 2025-12-31 | $8.69M | -6.5% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $66.05M | +36.0% |
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $36.81M | +47.2% |
Compare ELUT, PASG, CRDF, SGMOQ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗